Jack Khouri, MD

Articles by Jack Khouri, MD

Craig Cole, MD, an expert on multiple myeloma, presenting slides

Cross Q&A: Role of Belantamab Mafodotin in MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 17th 2023

The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.

DREAMM-3: Belantamab Mafodotin in Patients With Relapsed/Refractory MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 10th 2023

Craig Cole, MD, reviews data from DREAMM-3 on the efficacy and safety of single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Faiz Anwer, MD, an expert on multiple myeloma, presenting slides

Cross Q&A: Clinical Application of Ixa-Len-Dex for Patients With MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 10th 2023

Experts on multiple myeloma discuss the clinical applications of ixazomib-lenalidomide-dexamethasone combination therapy.

John Molina, MD, MEd, an expert on chronic myeloid leukemia

OPTIC Trial: 3-Year Data Update in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

John C. Molina, MD, EdM, reviews data from the 3-year update from the OPTIC study, and other experts offer their impressions.

Charles A. Schiffer, MD, an expert on chronic myeloid leukemia

Clinical Applications for Asciminib in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

Experts in the field of chronic myeloid leukemia discuss the role of asciminib in the overall treatment landscape.

REMIX: Real-World Effectiveness of Ixazomib with Lenalidomide and Dexamethasone in MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

Faiz Answer, MD, FACP, reviews data from the REMIX study on the real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Jeffrey A. Zonder, MD, an expert on multiple myeloma

Cross Q&A: Retrospective Study of Patients With MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.

ASCEMBL: Recent Data Updates for Asciminib in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

Charles A. Schiffer, MD, reviews clinical trial data for asciminib in chronic myeloid leukemia and highlights financial toxicity concerns.

Moaath Mustafa Ali, MD, MPH, an expert on chronic myeloid leukemia

Potential Role of Olverembatinib in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

The expert panel discusses the potential role of olverembatinib in the chronic myeloid leukemia treatment landscape.

Outcomes After Biochemical or Clinical Progression in Patients with MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

Jeffrey A. Zonder, MD, reviews data on patient outcomes following biochemical or clinical progression in multiple myeloma.

Jack Khouri, MD, an expert on multiple myeloma

Cross Q&A: Efficacy of CAR T-Cell Therapy in MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

The expert panel discusses the efficacy and durability of response of ciltacabtagene autoleucel in patients with multiple myeloma.

Olverembatinib in Patients with Pretreated/Refractory CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Moaath Mustafa Ali, MD, MPH, reviews data on olverembatinib in patients with heavily pretreated/refractory chronic myeloid leukemia.

Jay Yang, MD, an expert on chronic myeloid leukemia, presenting clinical trial data

Treatment Considerations for Ponatinib in Patients With CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.

CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Andrew Kin, MD, an expert on multiple myeloma

Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.

Ponatinib Dose-Ranging Data in Chronic-Phase CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

Jay Yang, MD, reviews data from the OPTIC trial, a ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia.

The host of Cancer Network's Face-Off program shown with an introductory slide

Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

A panel of experts on chronic myeloid leukemia from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in the disease space.

ALLIANCE A061202: Ixazomib Plus Pomalidomide and Dexamethasone in Multiple Myeloma

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.

Team Introductions: MM Experts From Karmanos Cancer Institute and Cleveland Clinic

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

A panel of experts on multiple myeloma from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in multiple myeloma.

Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

July 5th 2023

The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.

Recent Data on Non-BCMA Targeting Bispecifics in R/R MM

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

June 28th 2023

Experts review recent data on non-BCMA-targeting bispecifics for the treatment of R/R MM.

Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

June 28th 2023

The panel discusses how non-BCMA-targeting bispecifics might be selected and sequenced in MM.

Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

June 21st 2023

Maria-Victoria Mateos, MD, PhD, presents the case of a 52-year-old patient with penta-exposed MM who receives treatment with a non-BCMA-targeting bispecific.

The Development of Bispecifics-Based Combination Therapies in MM

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

June 21st 2023

Dr Maria-Victoria Mateos shares her expert perspectives on current efficacy and safety data on combination strategies with bispecifics in relapsed/refractory MM.

Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

June 14th 2023

The panel discusses how they would approach the treatment of a patient with relapsed/refractory MM who progresses on BCMA-targeting bispecifics.

Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

June 14th 2023

Melissa Alsina, MD, presents the case of a 39-year-old patient with multiple myeloma who has disease progression after initially responding to teclistamab.

Treatment with Teclistamab Following Progression on CAR-T in R/R MM

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

June 7th 2023

The panel shares their experiences with the sequencing of BCMA-targeting therapies in MM, with particular focus on treatment of patients who progress on CAR T-cell therapy with teclistamab.

Bispecific Antibodies in Development for the Treatment of R/R MM

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

June 7th 2023

Dr Jack Khouri highlights recent data updates on other BCMA-targeting bispecific antibodies that are in clinical development in multiple myeloma.

Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

May 31st 2023

Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.

Mechanism of Action of Teclistamab in R/R MM and Data Updates

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

May 31st 2023

Melissa Alsina, MD, explains the mechanism of action, data updates and dosing schedule of the BCMA-targeting bispecific antibody teclistamab.

Latest Updated Articles

Clinical Practice Perspectives on Treatment of MM with Bispecifics
Published: February 24th 2023 | Updated:
Selecting and Sequencing Bispecifics and CAR-T Therapies in R/R MM
Published: February 16th 2023 | Updated:
Cross Q&A: Retrospective Study of Patients With MM
Published: November 3rd 2023 | Updated:
Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics
Published: June 14th 2023 | Updated:
Patient Case 3: Relapsed/Refractory Multiple Myeloma
Published: February 16th 2023 | Updated:
Mechanism of Action of Teclistamab in R/R MM and Data Updates
Published: May 31st 2023 | Updated:

Jack Khouri, MD

Articles by Jack Khouri, MD

Cross Q&A: Role of Belantamab Mafodotin in MM

DREAMM-3: Belantamab Mafodotin in Patients With Relapsed/Refractory MM

Cross Q&A: Clinical Application of Ixa-Len-Dex for Patients With MM

OPTIC Trial: 3-Year Data Update in CML

Clinical Applications for Asciminib in CML

REMIX: Real-World Effectiveness of Ixazomib with Lenalidomide and Dexamethasone in MM

Cross Q&A: Retrospective Study of Patients With MM

ASCEMBL: Recent Data Updates for Asciminib in CML

Potential Role of Olverembatinib in CML

Outcomes After Biochemical or Clinical Progression in Patients with MM

Cross Q&A: Efficacy of CAR T-Cell Therapy in MM

Olverembatinib in Patients with Pretreated/Refractory CML

Treatment Considerations for Ponatinib in Patients With CML

CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM

Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma

Ponatinib Dose-Ranging Data in Chronic-Phase CML

Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic

ALLIANCE A061202: Ixazomib Plus Pomalidomide and Dexamethasone in Multiple Myeloma

Team Introductions: MM Experts From Karmanos Cancer Institute and Cleveland Clinic

Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment

Recent Data on Non-BCMA Targeting Bispecifics in R/R MM

Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM

Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific

The Development of Bispecifics-Based Combination Therapies in MM

Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics

Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab

Treatment with Teclistamab Following Progression on CAR-T in R/R MM

Bispecific Antibodies in Development for the Treatment of R/R MM

Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM

Mechanism of Action of Teclistamab in R/R MM and Data Updates

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Revumenib in R/R NPM1-Mutant AML

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma